Gallant medical supply code#
Gallant medical supply trial#

Gallant medical supply code#

The code identifying the type of other name. The other organization name is the alternative last name by which the provider is or has been known (if an individual) or other name by which the organization provider is or has been known. These components are often separately licensed or certified by States and may exist at physical locations other than that of the hospital of which they are a component. Hospital components include outpatient departments, surgical centers, psychiatric units, and laboratories. Subparts are the components and separate physical locations of organization health care providers. 2 = Non-person: entity other than an individual human being that furnishes health care (Examples: hospital, SNF, hospital subunit, pharmacy, or HMO).

1 = Person: individual human being who furnishes health care.The entity type code describes the type of health care provider that is being assigned an NPI. This address may contain the same information as the provider location address. The mailing address of the provider being identified. This address cannot include a Post Office box. For providers with more than one physical location, this is the primary location. The location address of the provider being identified.

The NPI is 10-position all-numeric identification number assigned by the NPPES to uniquely identify a health care provider. “The future is bright at Daiichi Sankyo as we are working on making further improvements to our ADC technology, along with discovering and developing other novel biologics, small molecules, gene and cell therapies in order to tackle cancer at every angle.What is the National Provider Indentifier (NPI)? I am very fortunate that I get to apply this experience at Daiichi Sankyo as we continue to advance science to create new medicines,” said Dr. “I’ve been fortunate to work on the development of medicines that have become standard of care to treat various forms of solid tumors including breast, ovarian, lung, gastric and prostate cancer along with blood cancers such as leukemia and lymphoma. Gallant unparalleled oncology expertise and led him to be promoted in 2019 to oversee the clinical development of Daiichi Sankyo’s entire oncology pipeline. Exposure to working on many different tumor types and learning the intricacies of many different types of cancer has given Dr. Gallant gained expertise in many critical aspects of medicine development, which eventually led to him leading both regional and global teams responsible for the strategic development of specific medicines or portfolio of medicines.Įvery cancer is different and requires different scientific approaches to try to treat each one. Starting as a clinical scientist and then holding roles of increasing responsibility across clinical development, Dr. Gallant spent close to 25 years in oncology clinical development at several companies including Bristol Myers Squibb, Human Genome Science and BioMarin across Canada, Europe and the United States. National Cancer Institute (NCI) that his specialization in cancer medicine development began.Īfter his academic training, Dr. It was during his doctoral studies in Canada where he synthesized new drug targets in collaboration with the U.S. Gallant to pursue advanced degrees in pharmacy and medicinal chemistry. Gallant was fascinated with the scientific process: how scientists put forward a hypothesis and then try to prove it. Now, he is looking to apply the lessons learned from this and other experiences to advance Daiichi Sankyo’s entire oncology pipeline and bring innovative treatment approaches to patients with cancer.

Gallant medical supply trial#

Gallant’s leadership, the company’s HER2 directed antibody drug conjugate (ADC) became one of the fastest biologics ever developed in oncology, taking only four years and four months from first patient enrolled into the phase 1 trial to an approval in the United States. Gallant heads a team of approximately 40 global clinical leads and physician scientists, who play an instrumental role in shaping the delivery of every medicine in the oncology pipeline of Daiichi Sankyo. Gilles Gallant, BPharm, PhD, FOPQ has spent the past three decades pursuing his passion for science and working to unravel the intricacies of cancer with the ultimate goal of crafting medicines to outsmart it.Īs the Senior Vice President, Global Head of Oncology Clinical Development, Dr.